UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 7, 2020
AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
000-50761
|
11-3146460
|
||
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
||
|
14 Plaza Drive Latham, New York 12110
|
||||
|
(Address of Principal Executive Offices) (Zip Code)
|
||||
|
(518) 795-1400
|
||||
|
(Registrant’s telephone number, including area code)
|
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.01 per share
|
ANGO
|
NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 – Results of Operations and Financial
Condition.
On January 7, 2020, AngioDynamics, Inc. (“AngioDynamics”) issued a press
release announcing financial results for the fiscal second quarter ended November 30, 2019. A copy of the press release is furnished herewith as Exhibit 99.1.
The information set forth in Item 2.02 of this Form 8-K (including
Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be
deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 7.01 – Regulation FD Disclosure.
Presentation slides discussing AngioDynamics and its fiscal second
quarter ended November 30, 2019 are furnished herewith as Exhibit 99.2.
The presentation slides furnished pursuant to Item 7.01 of this Form 8-K
(including Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by
reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Forward-Looking Statements
This document and its attachments contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures,
products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,”
“estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are
cautioned that actual events or results may differ from AngioDynamics’ expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new
products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively
compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials,
overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability
claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate
fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including
but not limited to its Annual Report on Form 10-K for the year ended May 31, 2019. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Item 9.01 – Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
Description
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ANGIODYNAMICS, INC.
(Registrant)
|
|||
|
Date: January 7, 2020
|
By:
|
/s/ Stephen A. Trowbridge | |
| Stephen A. Trowbridge | |||
|
Senior Vice President, General Counsel and
Interim Chief Financial Officer
|
|||
Exhibit 99.1
PRESS RELEASE
Investor Contact:
AngioDynamics, Inc.
Stephen Trowbridge, SVP General Counsel and Interim CFO
(518) 795-1408
AngioDynamics Reports Fiscal 2020 Second Quarter Financial Results
|
•
|
Net sales of $70.0 million, flat compared to the prior-year quarter
|
|
•
|
Gross margin increased 140 basis points year over year to 59.3%
|
|
•
|
GAAP loss per share of $0.07; adjusted earnings per share of $0.06
|
|
•
|
Announces the acquisition of C3 Wave PICC tip location system subsequent to quarter end
|
Latham, New York, January 7, 2020 – AngioDynamics, Inc. (NASDAQ: ANGO), a
leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the second quarter of fiscal year 2020, which ended November 30, 2019.
“Sales growth of 2.5%, ex-Asclera, exhibited continued momentum during the quarter, and I am pleased with the resulting gross margin expansion and
profitability,” commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. “We are making excellent progress on the integration of Eximo Medical and are currently building out a dedicated commercial organization to support a
product launch in the second half of our fiscal year 2020. I’m also excited to announce the acquisition of the C3 Wave tip location product, which will fill a technology gap in our portfolio and enable broader market adoption of our innovative BioFlo
PICCs. Looking ahead, strong growth in sales of our AngioVac and NanoKnife products during the quarter should position us well to achieve our full-year guidance and drive growth across our portfolio.”
Second Quarter 2020 Financial Results
Net sales for the second quarter of fiscal 2020, which now include the fiscal year 2019 acquisitions of BioSentry and RadiaDyne as organic revenue, were $70.0
million, flat compared to the prior-year quarter. Excluding the impact of Asclera sales, which were discontinued during fiscal year 2019, net sales grew 2.5% year over year. Foreign currency translation did not have a significant impact on the
Company’s sales in the quarter.
• Oncology net sales were $16.1 million, an increase of 5.1% from $15.3
million a year ago, led by higher sales of NanoKnife and the Alatus and IsoLoc balloon products.
• Vascular Interventions and Therapies (“VIT”) net sales were $31.2
million, an increase of 0.6%, compared to $31.0 million a year ago. Excluding last year’s Asclera sales of $1.7 million in the second quarter, VIT grew 6.5%, driven by growth in sales of the Company’s AngioVac and core VIT products.
• Vascular Access net sales were $22.8 million, a decrease of 4.0% from
$23.7 million a year ago, due primarily to lower sales of Ports and PICCs.
Excluding Asclera, U.S. net sales in the second quarter of fiscal 2020 were $55.6 million, an increase of 1.8% from $54.6 million a year ago, and International
net sales were $14.4 million, an increase of 5.6% from $13.7 million a year ago.
Gross margin for the second quarter of fiscal 2020 was 59.3%, an increase of 140 basis points compared to the second quarter of fiscal 2019, driven primarily
by productivity and supply chain improvements as well as positive product mix.
The Company recorded a net loss from continuing operations of $2.7 million, or a loss of $0.07 per share, in the second quarter of fiscal 2020. This compares
to a net loss from continuing operations of approximately $3.6 million, or a loss of $0.10 per share, a year ago.
Excluding the items shown in the non-GAAP reconciliation table below, adjusted net income for the second quarter of fiscal 2020 was $2.2 million, or $0.06 per
share, compared to adjusted net income of $2.9 million, or $0.07 per share, in the second quarter of fiscal 2019.
Adjusted EBITDA in the second quarter of fiscal 2020, excluding the items shown in the reconciliation table below, was $6.4 million, compared to $9.0 million
in the second quarter of fiscal 2019.
In the second quarter of fiscal 2020, the Company used $5.9 million in operating cash and had capital expenditures of $2.6 million. As of November 30, 2019,
the Company had $41.2 million in cash and cash equivalents and no debt outstanding.
Six Months Financial Results
For the six months ended November 30, 2019:
|
•
|
Net sales were $136.0 million, an increase of 1.6%, compared to $133.9 million for the same period a year ago. Excluding the impact of Asclera, sales of which were discontinued during fiscal
year 2019, net sales grew 4.0% year over year.
|
|
•
|
The Company's net loss from continuing operations was $4.0 million, or a loss of $0.11 per share, compared to a net loss from continuing operations of $9.3 million, or a loss of $0.25 per
share, a year ago.
|
|
•
|
Gross margin improved 150 basis points to 58.6% from 57.1% a year ago.
|
|
•
|
Excluding the items shown in the non-GAAP reconciliation table below, adjusted net income was $5.3 million, or $0.14 per share, compared to adjusted net income of $3.6 million, or $0.09 per
share, a year ago.
|
|
•
|
Adjusted EBITDA, excluding the items shown in the reconciliation table below, was $13.7 million, compared to $14.4 million for the same period a year ago.
|
C3 Wave PICC Tip Location Acquisition
Today, the Company announces the acquisition of the C3 Wave PICC tip location system from Medical Components Inc. This innovative, wireless, app-based ECG
system eliminates the need for a confirmatory chest x-ray of PICC tip placement, allowing greater patient access to the Company’s proprietary BioFlo PICCs. The C3 Wave PICC tip location system has received FDA 510k, CE, Health Canada, and other
international approvals.
Fiscal Year 2020 Financial Guidance
The Company reiterates its fiscal year 2020 guidance, which includes investments related to the full-market launch of the products acquired from Eximo
anticipated in the second half of the fiscal year.
Specifically, the Company continues to expect net sales in the range of $280 to $286 million and gross margin in the range of 58% to 59%. Adjusted earnings per
share is expected in the range of $0.10 to $0.15.
Conference Call
The Company’s management will host a conference call today at 8:00 a.m. ET to discuss its fiscal 2020 second quarter results.
To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13697417.
This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one
hour after the end of the call.
A recording of the call will also be available from 11:00 a.m. ET on Tuesday, January 7, 2020, until 11:59 p.m. ET on Tuesday, January 14, 2020. To hear this
recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13697417.
Use of Non-GAAP Measures
Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in
AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has
reported adjusted EBITDA, adjusted net income, adjusted earnings per share, free cash flow and net sales excluding Asclera. Management uses these measures in its internal analysis and review of operational performance. Management believes that these
measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying
business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to
time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.
About AngioDynamics, Inc.
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access,
peripheral vascular disease, and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. For
more information, visit www.angiodynamics.com.
Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding
AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for
future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking
statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect
the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or
assertions that AngioDynamics' technology infringes the technology of fourth parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory
agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to fourth-party distributors or joint
venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit
and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate acquired
businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2019. AngioDynamics does not assume any obligation to publicly update
or revise any forward-looking statements for any reason.
In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft
tissue and is similarly approved for commercialization in Canada, the European Union, and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.
|
CONSOLIDATED INCOME STATEMENTS
|
|
|
(in thousands, except per share data)
|
|
Three months ended
|
Six months ended
|
||||||||||||||
|
November 30,
|
November 30,
|
November 30,
|
November 30,
|
||||||||||||
|
2019
|
2018
|
2019
|
2018
|
||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||
|
Net sales
|
$
|
70,003
|
$
|
69,985
|
$
|
136,045
|
$
|
133,928
|
|||||||
|
Cost of sales (exclusive of intangible amortization)
|
28,459
|
29,433
|
56,284
|
57,423
|
|||||||||||
|
Gross profit
|
41,544
|
40,552
|
79,761
|
76,505
|
|||||||||||
|
% of net sales
|
59.3
|
%
|
57.9
|
%
|
58.6
|
%
|
57.1
|
%
|
|||||||
|
Operating expenses
|
|||||||||||||||
|
Research and development
|
7,764
|
7,076
|
14,055
|
14,450
|
|||||||||||
|
Sales and marketing
|
20,113
|
19,263
|
39,493
|
37,669
|
|||||||||||
|
General and administrative
|
10,994
|
9,262
|
19,448
|
17,697
|
|||||||||||
|
Amortization of intangibles
|
4,530
|
4,506
|
8,398
|
7,939
|
|||||||||||
|
Change in fair value of contingent consideration
|
145
|
244
|
(303
|
)
|
256
|
||||||||||
|
Acquisition, restructuring and other items, net
|
1,421
|
2,728
|
2,921
|
7,150
|
|||||||||||
|
Total operating expenses
|
44,967
|
43,079
|
84,012
|
85,161
|
|||||||||||
|
Operating income
|
(3,423
|
)
|
(2,527
|
)
|
(4,251
|
)
|
(8,656
|
)
|
|||||||
|
Interest expense, net
|
(41
|
)
|
(1,330
|
)
|
(506
|
)
|
(2,247
|
)
|
|||||||
|
Other income, net
|
162
|
80
|
64
|
194
|
|||||||||||
|
Total other (expense), net
|
121
|
(1,250
|
)
|
(442
|
)
|
(2,053
|
)
|
||||||||
|
Loss from continuing operations before income taxes
|
(3,302
|
)
|
(3,777
|
)
|
(4,693
|
)
|
(10,709
|
)
|
|||||||
|
Income tax benefit
|
(566
|
)
|
(190
|
)
|
(682
|
)
|
(1,418
|
)
|
|||||||
|
Net loss from continuing operations
|
(2,736
|
)
|
(3,587
|
)
|
(4,011
|
)
|
(9,291
|
)
|
|||||||
|
Net income from discontinued operations
|
—
|
5,727
|
—
|
10,962
|
|||||||||||
|
Net income (loss)
|
$
|
(2,736
|
)
|
$
|
2,140
|
$
|
(4,011
|
)
|
$
|
1,671
|
|||||
|
Loss per share - continuing operations
|
|||||||||||||||
|
Basic
|
$
|
(0.07
|
)
|
$
|
(0.10
|
)
|
$
|
(0.11
|
)
|
$
|
(0.25
|
)
|
|||
|
Diluted
|
$
|
(0.07
|
)
|
$
|
(0.10
|
)
|
$
|
(0.11
|
)
|
$
|
(0.25
|
)
|
|||
|
Income per share - discontinued operations
|
|||||||||||||||
|
Basic
|
$
|
—
|
$
|
0.15
|
$
|
—
|
$
|
0.29
|
|||||||
|
Diluted
|
$
|
—
|
$
|
0.15
|
$
|
—
|
$
|
0.29
|
|||||||
|
Income (loss) per share
|
|||||||||||||||
|
Basic
|
$
|
(0.07
|
)
|
$
|
0.06
|
$
|
(0.11
|
)
|
$
|
0.04
|
|||||
|
Diluted
|
$
|
(0.07
|
)
|
$
|
0.06
|
$
|
(0.11
|
)
|
$
|
0.04
|
|||||
|
Weighted average shares outstanding
|
|||||||||||||||
|
Basic
|
37,992
|
37,500
|
37,887
|
37,411
|
|||||||||||
|
Diluted
|
37,992
|
37,500
|
37,887
|
37,411
|
|||||||||||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
GAAP TO NON-GAAP RECONCILIATION
|
|
(in thousands, except per share data)
|
|
Reconciliation of Net Loss to non-GAAP Adjusted Net Income:
|
|||||||||||||||
|
Three months ended
|
Six months ended
|
||||||||||||||
|
November 30,
|
November 30,
|
November 30,
|
November 30,
|
||||||||||||
|
2019
|
2018
|
2019
|
2018
|
||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||
|
Net loss from continuing operations
|
$
|
(2,736
|
)
|
$
|
(3,587
|
)
|
$
|
(4,011
|
)
|
$
|
(9,291
|
)
|
|||
|
Amortization of intangibles
|
4,530
|
4,506
|
8,398
|
7,939
|
|||||||||||
|
Change in fair value of contingent consideration
|
145
|
244
|
(303
|
)
|
256
|
||||||||||
|
Acquisition, restructuring and other items, net (1)
|
1,421
|
2,728
|
2,921
|
7,150
|
|||||||||||
|
Write-off of deferred financing fees (2)
|
—
|
—
|
593
|
—
|
|||||||||||
|
Tax effect of non-GAAP items (3)
|
(1,209
|
)
|
(1,041
|
)
|
(2,273
|
)
|
(2,484
|
)
|
|||||||
|
Adjusted net income
|
$
|
2,151
|
$
|
2,850
|
$
|
5,325
|
$
|
3,570
|
|||||||
|
Reconciliation of Diluted Earnings Per Share to non-GAAP Adjusted Diluted Earnings Per Share:
|
|||||||||||||||
|
Three months ended
|
Six months ended
|
||||||||||||||
|
November 30,
|
November 30,
|
November 30,
|
November 30,
|
||||||||||||
|
2019
|
2018
|
2019
|
2018
|
||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||
|
Diluted loss per share
|
$
|
(0.07
|
)
|
$
|
(0.10
|
)
|
$
|
(0.11
|
)
|
$
|
(0.25
|
)
|
|||
|
Amortization of intangibles
|
0.12
|
0.12
|
0.22
|
0.21
|
|||||||||||
| Change in fair value of contingent consideration | — | 0.01 |
(0.01 |
) |
0.01 |
||||||||||
|
Acquisition, restructuring and other items, net (1)
|
0.04
|
0.07
|
0.08
|
0.19
|
|||||||||||
|
Write-off of deferred financing fees (2)
|
—
|
—
|
0.02
|
—
|
|||||||||||
|
Tax effect of non-GAAP items (3)
|
(0.04
|
)
|
(0.03
|
)
|
(0.06
|
)
|
(0.07
|
)
|
|||||||
|
Adjusted diluted earnings per share
|
$
|
0.06
|
$
|
0.07
|
$
|
0.14
|
$
|
0.09
|
|||||||
|
Adjusted diluted sharecount
|
38,092
|
38,117
|
38,120
|
38,131
|
|||||||||||
|
(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.
|
|
(2) Deferred financing fees related to the old credit agreement were written off during the first quarter of fiscal year 2020.
|
|
(3) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for November
30, 2019 and 2018.
|
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
GAAP TO NON-GAAP RECONCILIATION (Continued)
|
|
(in thousands, except per share data)
|
|
Reconciliation of Net Income Adjusted EBITDA:
|
|||||||||||||||
|
Three months ended
|
Six months ended
|
||||||||||||||
|
November 30,
|
November 30,
|
November 30,
|
November 30,
|
||||||||||||
|
2019
|
2018
|
2019
|
2018
|
||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||
|
Net loss from continuing operations
|
$
|
(2,736
|
)
|
$
|
(3,587
|
)
|
$
|
(4,011
|
)
|
$
|
(9,291
|
)
|
|||
|
Income tax expense (benefit)
|
(566
|
)
|
(190
|
)
|
(682
|
)
|
(1,418
|
)
|
|||||||
|
Interest expense, net
|
41
|
1,330
|
506
|
2,247
|
|||||||||||
|
Depreciation and amortization
|
5,863
|
5,890
|
11,033
|
10,698
|
|||||||||||
|
Change in fair value of contingent consideration
|
145
|
244
|
(303
|
)
|
256
|
||||||||||
|
Stock based compensation
|
2,242
|
2,583
|
4,226
|
4,726
|
|||||||||||
|
Acquisition, restructuring and other items, net (1)
|
1,421
|
2,728
|
2,921
|
7,150
|
|||||||||||
|
Adjusted EBITDA
|
$
|
6,410
|
$
|
8,998
|
$
|
13,690
|
$
|
14,368
|
|||||||
|
Per diluted share:
|
|||||||||||||||
|
Adjusted EBITDA
|
$
|
0.17
|
$
|
0.24
|
$
|
0.36
|
$
|
0.38
|
|||||||
|
(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.
|
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY
|
|
(in thousands)
|
| Three months ended |
Six months ended |
||||||||||||||||||||||||||
|
Nov 30,
2019
|
Nov 30,
2018
|
%
Growth
|
Currency
Impact
|
Constant
Currency
Growth
|
Nov 30,
2019
|
Nov 30,
2018
|
%
Growth
|
Currency
Impact
|
Constant
Currency
Growth
|
||||||||||||||||||
| Net Sales by Product Category |
|||||||||||||||||||||||||||
|
Vascular Interventions & Therapies
|
$
|
31,150
|
$
|
30,976
|
0.6%
|
$
|
60,063
|
$
|
59,573
|
0.8%
|
|||||||||||||||||
|
Vascular Access
|
22,784
|
23,723
|
(4.0)%
|
45,943
|
47,513
|
(3.3)%
|
|||||||||||||||||||||
|
Oncology
|
16,069
|
15,286
|
5.1%
|
30,039
|
26,842
|
11.9%
|
|||||||||||||||||||||
|
$
|
70,003
|
$
|
69,985
|
0.0%
|
0.0%
|
0.2%
|
$
|
136,045
|
$
|
133,928
|
1.6%
|
0.0%
|
1.8%
|
||||||||||||||
|
—
|
—
|
||||||||||||||||||||||||||
|
Net Sales by Geography
|
|||||||||||||||||||||||||||
|
United States
|
$
|
55,555
|
$
|
56,300
|
(1.3)%
|
0.0%
|
(1.3)%
|
$
|
108,492
|
$
|
107,796
|
0.6%
|
0.0%
|
0.6%
|
|||||||||||||
|
International
|
14,448
|
13,685
|
5.6%
|
1.0%
|
6.6%
|
27,553
|
26,132
|
5.4%
|
2.0%
|
6.5%
|
|||||||||||||||||
|
$
|
70,003
|
$
|
69,985
|
0.0%
|
0.0%
|
0.2%
|
$
|
136,045
|
$
|
133,928
|
1.6%
|
0.0%
|
1.8%
|
||||||||||||||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
CONSOLIDATED BALANCE SHEETS
|
|
(in thousands)
|
|
November 30, 2019
|
May 31, 2019
|
||||||
|
(unaudited)
|
(audited)
|
||||||
|
Assets
|
|||||||
|
Current assets:
|
|||||||
|
Cash and cash equivalents
|
$
|
41,247
|
$
|
227,641
|
|||
|
Total cash and investments
|
41,247
|
227,641
|
|||||
|
Accounts receivable, net
|
33,994
|
43,577
|
|||||
|
Inventories
|
50,239
|
40,071
|
|||||
|
Prepaid expenses and other
|
6,496
|
4,003
|
|||||
|
Total current assets
|
131,976
|
315,292
|
|||||
|
Property, plant and equipment, net
|
27,508
|
24,258
|
|||||
|
Other assets
|
8,976
|
3,835
|
|||||
|
Intangible assets, net
|
196,325
|
145,387
|
|||||
|
Goodwill
|
360,094
|
347,666
|
|||||
|
Total assets
|
$
|
724,879
|
$
|
836,438
|
|||
|
Liabilities and stockholders' equity
|
|||||||
|
Current liabilities:
|
|||||||
|
Accounts payable
|
$
|
17,968
|
$
|
22,829
|
|||
|
Accrued liabilities
|
28,478
|
38,338
|
|||||
|
Current portion of long-term debt
|
—
|
7,500
|
|||||
|
Current portion of contingent consideration
|
889
|
4,635
|
|||||
|
Other current liabilities
|
9,670
|
—
|
|||||
|
Total current liabilities
|
57,005
|
73,302
|
|||||
|
Long-term debt, net of current portion
|
—
|
124,407
|
|||||
|
Deferred income taxes
|
24,586
|
14,542
|
|||||
|
Contingent consideration, net of current portion
|
25,986
|
8,851
|
|||||
|
Other long-term liabilities
|
3,492
|
521
|
|||||
|
Total liabilities
|
111,069
|
221,623
|
|||||
|
Stockholders' equity
|
613,810
|
614,815
|
|||||
|
Total Liabilities and Stockholders' Equity
|
$
|
724,879
|
$
|
836,438
|
|||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
(in thousands)
|
|
Three months ended
|
Six months ended
|
|||||||||||||||
|
November 30,
|
November 30,
|
November 30,
|
November 30,
|
|||||||||||||
|
2019
|
2018
|
2019
|
2018
|
|||||||||||||
|
Cash flows from operating activities:
|
(unaudited)
|
(unaudited)
|
||||||||||||||
|
Net income (loss) from continuing operations
|
$
|
(2,736
|
)
|
$
|
2,140
|
$
|
(4,011
|
)
|
$
|
1,671
|
||||||
|
Adjustments to reconcile net loss to net cash provided by operating activities:
|
||||||||||||||||
|
Depreciation and amortization
|
5,903
|
6,692
|
11,110
|
12,291
|
||||||||||||
|
Non-cash lease expense
|
904
|
—
|
904
|
—
|
||||||||||||
|
Stock based compensation
|
2,242
|
2,591
|
4,226
|
4,741
|
||||||||||||
|
Change in fair value of contingent consideration
|
145
|
244
|
(303
|
)
|
256
|
|||||||||||
|
Deferred income taxes
|
(559
|
)
|
505
|
(734
|
)
|
495
|
||||||||||
|
Change in accounts receivable allowances
|
652
|
153
|
199
|
(75
|
)
|
|||||||||||
|
Fixed and intangible asset impairments and disposals
|
270
|
12
|
369
|
12
|
||||||||||||
|
Write-off of other assets
|
—
|
—
|
593
|
—
|
||||||||||||
|
Other
|
(19
|
)
|
(42
|
)
|
(27
|
)
|
(17
|
)
|
||||||||
|
Changes in operating assets and liabilities, net of acquisitions:
|
||||||||||||||||
|
Accounts receivable
|
(2,010
|
)
|
(2,506
|
)
|
9,464
|
(3,068
|
)
|
|||||||||
|
Inventories
|
(4,856
|
)
|
(194
|
)
|
(10,009
|
)
|
(955
|
)
|
||||||||
|
Prepaid expenses and other
|
(2,798
|
)
|
17
|
(3,544
|
)
|
(1,183
|
)
|
|||||||||
|
Accounts payable, accrued and other liabilities
|
8,799
|
3,347
|
(8,834
|
)
|
(10,082
|
)
|
||||||||||
|
Net cash provided by (used in) operating activities
|
5,937
|
12,959
|
(597
|
)
|
4,086
|
|||||||||||
|
Cash flows from investing activities:
|
||||||||||||||||
|
Additions to property, plant and equipment
|
(2,623
|
)
|
(734
|
)
|
(4,014
|
)
|
(1,416
|
)
|
||||||||
|
Acquisition of intangibles
|
(200
|
)
|
—
|
(350
|
)
|
—
|
||||||||||
|
Cash paid in acquisition
|
(45,760
|
)
|
(47,920
|
)
|
(45,760
|
)
|
(84,920
|
)
|
||||||||
|
Net cash used in investing activities
|
(48,583
|
)
|
(48,654
|
)
|
(50,124
|
)
|
(86,336
|
)
|
||||||||
|
Cash flows from financing activities:
|
||||||||||||||||
|
Proceeds from issuance of long-term debt
|
—
|
55,000
|
—
|
55,000
|
||||||||||||
|
Repayment of long-term debt
|
—
|
(1,250
|
)
|
(132,500
|
)
|
(2,500
|
)
|
|||||||||
|
Deferred financing costs on long-term debt
|
—
|
—
|
(741
|
)
|
—
|
|||||||||||
|
Payment of contingent consideration previously established in purchase accounting
|
—
|
—
|
(1,208
|
)
|
(2,100
|
)
|
||||||||||
|
Proceeds (outlays) from exercise of stock options and employee stock purchase plan
|
—
|
149
|
(1,300
|
)
|
854
|
|||||||||||
|
Net cash provided by (used in) financing activities
|
—
|
53,899
|
(135,749
|
)
|
51,254
|
|||||||||||
|
Effect of exchange rate changes on cash and cash equivalents
|
244
|
(146
|
)
|
76
|
(280
|
)
|
||||||||||
|
Decrease in cash and cash equivalents
|
(42,402
|
)
|
18,058
|
(186,394
|
)
|
(31,276
|
)
|
|||||||||
|
Cash and cash equivalents at beginning of period
|
83,649
|
24,762
|
227,641
|
74,096
|
||||||||||||
|
Cash and cash equivalents at end of period
|
$
|
41,247
|
$
|
42,820
|
$
|
41,247
|
$
|
42,820
|
||||||||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
GAAP TO NON-GAAP RECONCILIATION
|
|
(in thousands)
|
|
Reconciliation of Free Cash Flows:
|
|||||||||||||||
|
Three months ended
|
Six months ended
|
||||||||||||||
|
November 30,
|
November 30,
|
November 30,
|
November 30,
|
||||||||||||
|
2019
|
2018
|
2019
|
2018
|
||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||
|
Net cash provided by (used in) operating activities
|
$
|
5,937
|
$
|
12,959
|
$
|
(597
|
)
|
$
|
4,086
|
||||||
|
Additions to property, plant and equipment
|
(2,623
|
)
|
(734
|
)
|
(4,014
|
)
|
(1,416
|
)
|
|||||||
|
Free Cash Flow
|
$
|
3,314
|
$
|
12,225
|
$
|
(4,611
|
)
|
$
|
2,670
|
||||||
Exhibit 99.2
AngioDynamics Second Quarter 2020 Earnings PresentationJanuary 7, 2020
Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital
expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,”
“believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and
uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to
develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of
AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending
or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product
recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance,
foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate acquired businesses, as well as the risk factors listed from time to time in
AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2019. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.In
the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and
Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.Notice Regarding Non-GAAP Financial MeasuresManagement uses non-GAAP measures to establish operational goals and believes that
non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting
measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported adjusted EBITDAS (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income; adjusted earnings per
shar, free cash flow and net sales on an organic basis, excluding acquired assets and Asclera. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide
investors with useful information in comparing AngioDynamics’ performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics’ underlying
business. Management encourages investors to review AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including those that may only occur from
time to time but have a material impact on AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP. Forward-Looking Statements
Second Quarter FY2020 Highlights Corporate Developments NanoKnife DIRECT study: 13 sites have IRB
approval to begin patient enrollment; anticipate approximately 5 more site approvals by end of fiscal year 2020.Received Category III CPT physician billing codes for irreversible electroporation.Announced the acquisition of the C3 Wave PICC tip
location system subsequent to quarter end. * Excluding Asclera, Venous Insufficiency growth was (1)%. Financial Performance Product Family Year-over-Year Sales Growth (in millions) Q2 FY20 Q2
FY19 Change Revenue $70.0 $70.0 0.0% Revenue Excluding Asclera $70.0 $68.3 2.5% Gross Margin 59.3% 57.9% 140 bps Adjusted EPS $0.06 $0.07 ($0.01) Adjusted EBITDA $6.4 $9.0 ($2.6) Cash Used in
Operations ($5.9) ($13.0) Free Cash Flow $3.3 $12.2 Vascular Interventions and Therapies AngioVac® 53% Thrombolytic (10%) Core Peripheral 3% Venous Insufficiency (17%)* Vascular
Access Midlines 0% PICCs (7%) Ports (9%) Dialysis 3% Oncology NanoKnife® 27% Solero® Microwave 2% BioSentry (4%) Alatus and IsoLoc Balloons 26% RadioFrequency Ablation (23%)
Second Quarter FY2020 Results (unaudited) $ in thousands (except per share data) FY2020Q2
Results FY2019Q2 Results Change FY2020YTD Results FY2019YTD Results Change Revenue Vascular Interventions and Therapies Vascular Access Oncology United States
International $70,00331,15022,78416,06955,55514,448 $69,98530,97623,72315,28656,30013,685 0.0%*0.6%*(4.0%)5.1%(1.3%)*5.6% $136,04560,06345,94330,039108,49227,553 $133,92859,57347,51326,842107,79626,132 1.6%*0.8%*(3.3%)11.9%0.6%*5.4% Net
Loss from Continuing OperationsAdjusted Net Income ($2,736)$2,151 ($3,587)$2,850 ($4,011)$5,325 ($9,291)$3,570 GAAP Loss Per ShareNon-GAAP Adjusted EPS ($0.07)$0.06 ($0.10)$0.07 ($0.11)$0.14 ($0.25)$0.09 Gross
Margin 59.3% 57.9% 58.6% 57.1% Adjusted EBITDA $6,410 $8,998 $13,690 $14,368 Free Cash
Flow $3,314 $12,225 ($4,611) $2,670 Cash $41,247 $227,641** $41,247 $227,641** Debt $0 $132,500** $0 $132,500** * When excluding Asclera: AngioDynamics growth was 2.5% FY20 Q2 and 4.0% YTD Vascular Interventions and
Therapies growth was 6.5% FY20 Q2 and 6.4% YTD U.S. growth was 1.8% FY20 Q2 and 3.7% YTD** Balances reflect amounts at May 31, 2019.
FY2020 Guidance RevenueAdjusted EPS Gross Margin Current Guidance (Unchanged)$280m - $286m$0.10 -
$0.1558% - 59%
GAAP to Non-GAAP Reconciliation
Reconciliation of GAAP to Non-GAAP Net Income and EPS Amounts in thousands Includes costs related to
merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.Deferred financing fees related to the old credit agreement were written off during the first
quarter of fiscal year 2020.Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for November 30, 2019
and 2018.
Reconciliation of Net Income Adjusted EBITDA Amounts in thousands
Growth through Focus Execution Accountability